Health technology assessment of varicella vaccine in the Armed Forces
- PMID: 35463553
- PMCID: PMC9023555
- DOI: 10.1016/j.mjafi.2021.06.010
Health technology assessment of varicella vaccine in the Armed Forces
Abstract
Background: The Indian Armed Forces, on entry, vaccinates all cadets and recruits with varicella vaccine for the prevention of varicella. This health technology assessment (HTA) report puts forth evidence for HTA of varicella vaccination in the Armed Forces in various domains namely clinical, societal, ethical, economic, and legal.
Methods: The policy question under each domain has been developed according to best-practice methods for HTA. The costs included were hospitalization cost due to varicella infection; training lost cost; the varicella vaccine cost; cost of the side effects of vaccine; and the outbreak investigation cost. The incremental cost-effectiveness ratio (ICER) for varicella cases averted and man-days saved, and quality-adjusted life years (QALYs) gained due to varicella vaccination strategy were calculated.
Results: Evidence suggests a reduction of 81% in hospitalization rates with 19392 man-days saved per 1 lakh population due to varicella vaccination strategy. The ICER for varicella cases averted is estimated to be Rs 56732/- per case averted and Rs 5687/- per man-day saved. QALYs gained due to two-dose varicella vaccination strategy is estimated to be 1152 per 1 lakh population with cost per QALY gained Rs 95735/-.
Conclusion: The study showed a large reduction in hospitalizations and consequently man-days lost after the introduction of the vaccination strategy. The QALYs was another aspect of importance brought out by this study. Thus, a two-dose vaccination strategy for varicella-zoster virus (VZV) for the Armed Forces trainees is a cost-effective policy.
Keywords: Chickenpox; Cost effectiveness; Health technology assessment; Varicella.
© 2022 Director General, Armed Forces Medical Services. Published by Elsevier, a division of RELX India Pvt. Ltd.
Conflict of interest statement
The authors have none to declare.
Figures
Similar articles
-
Cost effectiveness and budget impact of universal varicella vaccination in Russia.Hum Vaccin Immunother. 2022 Nov 30;18(5):2045152. doi: 10.1080/21645515.2022.2045152. Epub 2022 Mar 8. Hum Vaccin Immunother. 2022. PMID: 35258445 Free PMC article.
-
Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: An economic evaluation using a dynamic transmission model.PLoS One. 2021 May 13;16(5):e0251644. doi: 10.1371/journal.pone.0251644. eCollection 2021. PLoS One. 2021. PMID: 33984060 Free PMC article.
-
Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.Vaccine. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8. Vaccine. 2013. PMID: 23306360
-
Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster.Clin Ther. 2015 Apr 1;37(4):830-841.e7. doi: 10.1016/j.clinthera.2015.01.006. Epub 2015 Feb 24. Clin Ther. 2015. PMID: 25721380
-
Cost-effectiveness of Varicella Vaccination Program in Iran.Int J Prev Med. 2017 Dec 5;8:103. doi: 10.4103/ijpvm.IJPVM_295_16. eCollection 2017. Int J Prev Med. 2017. PMID: 29291045 Free PMC article.
Cited by
-
Systematic review of economic evaluations of varicella vaccination programmes.PLoS One. 2023 Mar 27;18(3):e0282327. doi: 10.1371/journal.pone.0282327. eCollection 2023. PLoS One. 2023. PMID: 36972249 Free PMC article.
-
Expanded spectrum of varicella disease and the need for vaccination in India.Hum Vaccin Immunother. 2024 Dec 31;20(1):2328955. doi: 10.1080/21645515.2024.2328955. Epub 2024 Mar 22. Hum Vaccin Immunother. 2024. PMID: 38517089 Free PMC article.
References
-
- Moffat J., Ku C.C., Zerboni L., et al. In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Arvin A., Campadelli-Fiume G., Mocarski E., et al., editors. Cambridge University Press; Cambridge: 2007. VZV: pathogenesis and the disease consequences of primary infection.https://www.ncbi.nlm.nih.gov/books/NBK47382/ Chapter 37. Available from: - PubMed
-
- Varicella (Chickenpox), Center for Disease Control and Prevention CDC, [accessed 14 May 2020] https://www.cdc.gov/chickenpox/about/transmission.html.
-
- Jane F Seward, Mona Marin, Varicella Disease Burden and Varicella Vaccines On behalf of the SAGE VZV Working Group, WHO SAGE Meeting April 2, 2014, CDC Immunization https://www.who.int/immunization/sage/meetings/2014/april/2_SAGE_April_V....
-
- Munech R., Nassim C., Nikku S. Sero-epidemiology of varicella. J Infect Dis. 1986;153:153–155. - PubMed
LinkOut - more resources
Full Text Sources